Status:

Do Not Prescribe (DNP), Red

Decision Date:

February 2019

Comments

RED

• NICE TA975 for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (Decision date - May 2024)

DNP: 

• NICE TA842 treating follicular lymphoma after 2 or more therapies. Terminated appraisal. (Decision date - December 2022)
• NICE TA933 for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. Terminated appraisal, replaces NICE TA567 (Decision - December 2023)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again